Jul 24 2012
In this post in the Results for Development Institute's "Center for Global Health R&D Policy Assessment" blog, Aarthi Rao, a program officer at the institute, examines whether corporate social responsibility (CSR) programs within Indian pharmaceutical companies can help fight neglected diseases. "Corporate giving amongst Indian pharmaceutical firms is still in its infancy and will likely evolve in the coming years as the industry continues to grow," the she writes, adding, "As the breadth of social initiatives increases, it will be interesting to watch whether the social arms of firms will join their business counterparts in increasing the availability of neglected disease technologies" (7/23).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |